{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:16Z","timestamp":1789587016583,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,30]]},"DOI":"10.7759\/cureus.51352","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T01:24:47Z","timestamp":1703985887000},"source":"Crossref","is-referenced-by-count":6,"title":["Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Idiopathic Inflammatory Myopathy: From Mechanisms of Action to Clinical Applications"],"prefix":"10.7759","author":[{"given":"Shilpa","family":"Rajagopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilis","family":"Mavratsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna K","family":"Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya L","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaila","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Glucagon-like-peptide-1 Receptor Agonists as Potential Treatments for Inflammatory Myopathies [Abstract D169 Resident Presentation]","volume":"71 (suppl 1)","author":"Alruwaili F","year":"2023","unstructured":"Alruwaili F, Lalani E, Raheem A, Raji M, Murthy V. Glucagon-like-peptide-1 Receptor Agonists as Potential Treatments for Inflammatory Myopathies [Abstract D169 Resident Presentation]. J Am Geriatr Soc. 2023, 71 (suppl 1):S317.","journal-title":"J Am Geriatr Soc"},{"key":"ref2","article-title":"Inflammatory myopathies","volume":"113","author":"Atluri RB","year":"2016","unstructured":"Atluri RB. Inflammatory myopathies. Mo Med. 2016, 113:127-30.","journal-title":"Mo Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg IE","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, et al.. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021, 7:86. 10.1038\/s41572-021-00321-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","article-title":"Autoimmune Myopathies","author":"Cheeti A","year":"2023","unstructured":"Cheeti A, Brent LH, Panginikkod S. Autoimmune Myopathies. StatPearls [Internet], Treasure Island (FL); 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2016.00064","article-title":"Idiopathic inflammatory myopathies: clinical approach and management","volume":"7","author":"Malik A","year":"2016","unstructured":"Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol. 2016, 7:64. 10.3389\/fneur.2016.00064","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd A","year":"2017","unstructured":"Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017, 17:322-8. 10.7861\/clinmedicine.17-4-322","journal-title":"Clin Med (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-018-0106-2","article-title":"Current treatment for myositis","volume":"4","author":"Barsotti S","year":"2018","unstructured":"Barsotti S, Lundberg IE. Current treatment for myositis. Curr Treatm Opt Rheumatol. 2018, 4:299-315. 10.1007\/s40674-018-0106-2","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12511","article-title":"Update on the pharmacological treatment of adult myositis","volume":"280","author":"Oddis CV","year":"2016","unstructured":"Oddis CV. Update on the pharmacological treatment of adult myositis. J Intern Med. 2016, 280:63-74. 10.1111\/joim.12511","journal-title":"J Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X11415306","article-title":"Diagnosis and treatment of the idiopathic inflammatory myopathies","volume":"3","author":"Gazeley DJ","year":"2011","unstructured":"Gazeley DJ, Cronin ME. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskelet Dis. 2011, 3:315-24. 10.1177\/1759720X11415306","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04302-y","article-title":"Disability in idiopathic inflammatory myopathies: questionnaire-based study","volume":"39","author":"Opinc AH","year":"2019","unstructured":"Opinc AH, Brzezi\u0144ska OE, Makowska JS. Disability in idiopathic inflammatory myopathies: questionnaire-based study. Rheumatol Int. 2019, 39:1213-20. 10.1007\/s00296-019-04302-y","journal-title":"Rheumatol Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7313-z","article-title":"Long-term follow-up of 62 patients with myositis","volume":"261","author":"van de Vlekkert J","year":"2014","unstructured":"van de Vlekkert J, Hoogendijk JE, de Visser M. Long-term follow-up of 62 patients with myositis. J Neurol. 2014, 261:992-8. 10.1007\/s00415-014-7313-z","journal-title":"J Neurol"},{"key":"ref12","unstructured":"Immunoforge Inc. receives U.S. FDA ODD for treatment of polymyositis. (2021). Accessed. August 20, 2023: https:\/\/www.prnewswire.com\/news-releases\/immunoforge-inc-receives-us-fda-odd-for-treatment-of-polymyositis-301384587....."},{"key":"ref13","unstructured":"Immunoforge\u2019s \u201cPF1801\u201d is designated as orphan drug by FDA. Markets. (2021). Accessed. August 20, 2023: https:\/\/markets.businessinsider.com\/news\/stocks\/immunoforge-s-pf1801-is-designated-as-orphan-drug-by-fda-1030015463."},{"key":"ref14","unstructured":"ImmunoForge pipeline. Pharmaceutical solutions based on long-acting technology. Accessed. August 20, 2023: https:\/\/www.immunoforge.com\/m21.php."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1090295","article-title":"User's guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer CF Jr","year":"2015","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015, 127:818-26. 10.1080\/00325481.2015.1090295","journal-title":"Postgrad Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti G","year":"2022","unstructured":"Bendotti G, Montefusco L, Lunati ME, et al.. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022, 182:106320. 10.1016\/j.phrs.2022.106320","journal-title":"Pharmacol Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi SF","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, et al.. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023, 14:1148209. 10.3389\/fimmu.2023.1148209","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee YS","year":"2016","unstructured":"Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016, 2016:3094642. 10.1155\/2016\/3094642","journal-title":"Mediators Inflamm"},{"key":"ref19","article-title":"Glucagon-Like Peptide-1 Receptor Agonists","author":"Collins L","year":"2023","unstructured":"Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls [Internet], Treasure Island (FL); 2023."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12434","article-title":"Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy","volume":"10","author":"Hong Y","year":"2019","unstructured":"Hong Y, Lee JH, Jeong KW, Choi CS, Jun HS. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle. 2019, 10:903-18. 10.1002\/jcsm.12434","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203546","article-title":"Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice","volume":"13","author":"Khin PP","year":"2021","unstructured":"Khin PP, Hong Y, Yeon M, Lee DH, Lee JH, Jun HS. Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice. Aging (Albany NY). 2021, 13:21962-74. 10.18632\/aging.203546","journal-title":"Aging (Albany NY)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111472","article-title":"Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats","volume":"539","author":"Yamada S","year":"2022","unstructured":"Yamada S, Ogura Y, Inoue K, et al.. Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Mol Cell Endocrinol. 2022, 539:111472. 10.1016\/j.mce.2021.111472","journal-title":"Mol Cell Endocrinol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119300","article-title":"GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway","volume":"1869","author":"Wu L","year":"2022","unstructured":"Wu L, Zhou M, Li T, Dong N, Yi L, Zhang Q, Mi M. GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway. Biochim Biophys Acta Mol Cell Res. 2022, 1869:119300. 10.1016\/j.bbamcr.2022.119300","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154044","article-title":"Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents","volume":"103","author":"Gurjar AA","year":"2020","unstructured":"Gurjar AA, Kushwaha S, Chattopadhyay S, et al.. Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents. Metabolism. 2020, 103:154044. 10.1016\/j.metabol.2019.154044","journal-title":"Metabolism"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13202","article-title":"Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle","volume":"19","author":"Abdulla H","year":"2020","unstructured":"Abdulla H, Phillips BE, Wilkinson DJ, et al.. Glucagon-like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle. Aging Cell. 2020, 19:e13202. 10.1111\/acel.13202","journal-title":"Aging Cell"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/medicines9090047","article-title":"The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a pilot study","volume":"9","author":"Ozeki Y","year":"2022","unstructured":"Ozeki Y, Masaki T, Kamata A, et al.. The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a pilot study. Medicines (Basel). 2022, 9:47. 10.3390\/medicines9090047","journal-title":"Medicines (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00283.2013","article-title":"GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle","volume":"306","author":"Sj\u00f8berg KA","year":"2014","unstructured":"Sj\u00f8berg KA, Holst JJ, Rattigan S, Richter EA, Kiens B. GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab. 2014, 306:E355-62. 10.1152\/ajpendo.00283.2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1465","article-title":"Vasodilatory actions of glucagon-like peptide 1 are preserved in skeletal and cardiac muscle microvasculature but not in conduit artery in obese humans with vascular insulin resistance","volume":"43","author":"Wang N","year":"2020","unstructured":"Wang N, Tan AW, Jahn LA, et al.. Vasodilatory actions of glucagon-like peptide 1 are preserved in skeletal and cardiac muscle microvasculature but not in conduit artery in obese humans with vascular insulin resistance. Diabetes Care. 2020, 43:634-42. 10.2337\/dc19-1465","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2011.03.018","article-title":"Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes","volume":"32","author":"Wang L","year":"2011","unstructured":"Wang L, Guo F, Wei S, Zhao R. Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes. Peptides. 2011, 32:1313-9. 10.1016\/j.peptides.2011.03.018","journal-title":"Peptides"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1073","article-title":"Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism","volume":"61","author":"Chai W","year":"2012","unstructured":"Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. 2012, 61:888-96. 10.2337\/db11-1073","journal-title":"Diabetes"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00473.2012","article-title":"Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment","volume":"304","author":"Dong Z","year":"2013","unstructured":"Dong Z, Chai W, Wang W, Zhao L, Fu Z, Cao W, Liu Z. Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab. 2013, 304:E222-8. 10.1152\/ajpendo.00473.2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-019-0513-y","article-title":"Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob\/ob mice","volume":"44","author":"Xu F","year":"2020","unstructured":"Xu F, Cao H, Chen Z, Gu H, Guo W, Lin B, Weng J. Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob\/ob mice. Int J Obes (Lond). 2020, 44:937-47. 10.1038\/s41366-019-0513-y","journal-title":"Int J Obes (Lond)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13025","article-title":"Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis","volume":"13","author":"Kamiya M","year":"2022","unstructured":"Kamiya M, Mizoguchi F, Yasuda S. Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis. J Cachexia Sarcopenia Muscle. 2022, 13:2118-31. 10.1002\/jcsm.13025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1042\/CS20130708","article-title":"GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans","volume":"127","author":"Subaran SC","year":"2014","unstructured":"Subaran SC, Sauder MA, Chai W, et al.. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond). 2014, 127:163-70. 10.1042\/CS20130708","journal-title":"Clin Sci (Lond)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.115.305447","article-title":"GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men","volume":"35","author":"Smits MM","year":"2015","unstructured":"Smits MM, Muskiet MH, Tonneijck L, Kramer MH, Diamant M, van Raalte DH, Sern\u00e9 EH. GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men. Arterioscler Thromb Vasc Biol. 2015, 35:1538-43. 10.1161\/ATVBAHA.115.305447","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.07.020","article-title":"Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes","volume":"30","author":"Liu J","year":"2016","unstructured":"Liu J, Hu Y, Zhang H, Xu Y, Wang G. Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes. J Diabetes Complications. 2016, 30:1555-9. 10.1016\/j.jdiacomp.2016.07.020","journal-title":"J Diabetes Complications"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac613","article-title":"Effects of GLP-1 infusion upon whole-body glucose uptake and skeletal muscle perfusion during Fed-state in older men","volume":"108","author":"Abdulla H","year":"2023","unstructured":"Abdulla H, Phillips B, Wilkinson D, et al.. Effects of GLP-1 infusion upon whole-body glucose uptake and skeletal muscle perfusion during Fed-state in older men. J Clin Endocrinol Metab. 2023, 108:971-8. 10.1210\/clinem\/dgac613","journal-title":"J Clin Endocrinol Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study","volume":"28","author":"Perna S","year":"2016","unstructured":"Perna S, Guido D, Bologna C, Solerte SB, Guerriero F, Isu A, Rondanelli M. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016, 28:1251-7. 10.1007\/s40520-015-0525-y","journal-title":"Aging Clin Exp Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205257-glucagon-like-peptide-1-receptor-agonists-in-the-treatment-of-idiopathic-inflammatory-myopathy-from-mechanisms-of-action-to-clinical-applications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:20Z","timestamp":1707509180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205257-glucagon-like-peptide-1-receptor-agonists-in-the-treatment-of-idiopathic-inflammatory-myopathy-from-mechanisms-of-action-to-clinical-applications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,30]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.51352","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,30]]}}}